27 citations
,
January 1984 in “Pharmacology & Therapeutics” This review discusses androgen manipulation strategies for conditions like benign prostatic hyperplasia and prostatic carcinoma but reports no new clinical results.
1 citations
,
December 2011 in “Arzneimittelforschung” This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” This study found that a specific amino-pyridine compound showed potent androgen receptor antagonist activity, stimulating hair growth in mice and reducing sebum production in a hamster model.
5 citations
,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” This study identified pantolactam based compounds as effective topical antagonists of the androgen receptor, reducing sebum components in a hamster model.
In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.